Naibec Receives Flood of Meetings at Bio USA... "Commitment to Funding Development of Inflammatory Bowel Disease Treatments"

[Asia Economy Reporter Jang Hyowon] Naivek, a peptide fusion bio-specialized company, announced on the 17th that it successfully secured a "funding commitment" related to the development of the inflammatory bowel disease treatment (NIPEP-IBD) while completing follow-up discussions with global pharmaceutical companies at Bio USA.

At Bio USA, which started on the 13th, Naivek concluded technical collaboration discussions on the next research phase with a global pharmaceutical company that has been collaborating to apply the representative drug delivery platform ‘NIPEP-TPP’. Along with the pulmonary fibrosis treatment (NP-201), which is approaching global Phase 1 clinical trials, the inflammatory bowel disease treatment (NIPEP-IBD) attracted interest from numerous bio companies, and meetings were held focusing on follow-up discussions. The inflammatory bowel disease treatment is planning a global Phase 1 clinical trial and successfully secured financial support commitments for additional experiments to be conducted in the future.

A company official stated, “At the ‘corporate presentation’ led by Naivek, we announced research results and plans focusing on the pulmonary fibrosis treatment (clinical trial code NP-201), which is advancing to global Phase 1 clinical trials, and future clinical entry, which received considerably more interest on-site than expected,” adding, “After the presentation, meetings with global pharmaceutical companies and key industry stakeholders flooded in, and we could not accommodate all the requests, so follow-up meetings have already been scheduled after returning to Korea following the event.”

He continued, “Last year, the drug delivery platform was mainly the subject of collaboration, but this year, not only the drug delivery platform but also ‘inflammation-related diseases’ such as pulmonary fibrosis treatment and inflammatory bowel disease treatment attracted significant interest,” emphasizing, “Although we cannot disclose the name at this stage, we achieved the outcome of receiving a financial support commitment for the inflammatory bowel disease treatment from one of the industry partners participating in this event.”

The financial support commitment for the inflammatory bowel disease treatment, which possesses not only inflammation control but also regenerative functions for damaged intestinal tissue, signifies that Naivek’s technology for the treatment under development has been externally validated. The company explained that this will provide a stepping stone to accelerate the development speed of the treatment and enhance its technological value.

Recently, Naivek obtained GMP certification for its peptide active pharmaceutical ingredient (API) facility and approval for the peptide API product, establishing a one-stop system from new drug research and development based on peptides to manufacturing. Based on this, the growth rate of the ‘peptide pharmaceutical business,’ a major growth engine, is expected to accelerate sharply. The foundational business in the dental bio-materials sector also turned profitable in the first quarter of this year, maintaining stable growth.